» Articles » PMID: 36947467

Covid-19 Surveillance Testing and Resident Outcomes in Nursing Homes

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2023 Mar 22
PMID 36947467
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite widespread adoption of surveillance testing for coronavirus disease 2019 (Covid-19) among staff members in skilled nursing facilities, evidence is limited regarding its relationship with outcomes among facility residents.

Methods: Using data obtained from 2020 to 2022, we performed a retrospective cohort study of testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among staff members in 13,424 skilled nursing facilities during three pandemic periods: before vaccine approval, before the B.1.1.529 (omicron) variant wave, and during the omicron wave. We assessed staff testing volumes during weeks without Covid-19 cases relative to other skilled nursing facilities in the same county, along with Covid-19 cases and deaths among residents during potential outbreaks (defined as the occurrence of a case after 2 weeks with no cases). We reported adjusted differences in outcomes between high-testing facilities (90th percentile of test volume) and low-testing facilities (10th percentile). The two primary outcomes were the weekly cumulative number of Covid-19 cases and related deaths among residents during potential outbreaks.

Results: During the overall study period, 519.7 cases of Covid-19 per 100 potential outbreaks were reported among residents of high-testing facilities as compared with 591.2 cases among residents of low-testing facilities (adjusted difference, -71.5; 95% confidence interval [CI], -91.3 to -51.6). During the same period, 42.7 deaths per 100 potential outbreaks occurred in high-testing facilities as compared with 49.8 deaths in low-testing facilities (adjusted difference, -7.1; 95% CI, -11.0 to -3.2). Before vaccine availability, high- and low-testing facilities had 759.9 cases and 1060.2 cases, respectively, per 100 potential outbreaks (adjusted difference, -300.3; 95% CI, -377.1 to -223.5), along with 125.2 and 166.8 deaths (adjusted difference, -41.6; 95% CI, -57.8 to -25.5). Before the omicron wave, the numbers of cases and deaths were similar in high- and low-testing facilities; during the omicron wave, high-testing facilities had fewer cases among residents, but deaths were similar in the two groups.

Conclusions: Greater surveillance testing of staff members at skilled nursing facilities was associated with clinically meaningful reductions in Covid-19 cases and deaths among residents, particularly before vaccine availability.

Citing Articles

The ratio between SARS-CoV-2 RNA viral load and culturable viral titre differs depending on the stage of infection: a case study of household transmission in an adult male.

Porter M, Viloria Winnett A, Hao L, Shelby N, Reyes J, Schlenker N Access Microbiol. 2025; 7(2).

PMID: 39967741 PMC: 11833051. DOI: 10.1099/acmi.0.000732.v3.


Measures to Prevent and Control COVID-19 in Skilled Nursing Facilities: A Scoping Review.

Canter B, Ulyte A, McGarry B, Barnett M JAMA Health Forum. 2025; 6(1):e245175.

PMID: 39888638 PMC: 11786235. DOI: 10.1001/jamahealthforum.2024.5175.


Association between delayed outbreak identification and SARS-CoV-2 infection and mortality among long-term care home residents, Ontario, Canada, March to November 2020: a cohort study.

Brown K, Buchan S, Chan A, Costa A, Daneman N, Garber G Euro Surveill. 2024; 29(41).

PMID: 39391999 PMC: 11484918. DOI: 10.2807/1560-7917.ES.2024.29.41.2300719.


Modeling the transmission mitigation impact of testing for infectious diseases.

Middleton C, Larremore D Sci Adv. 2024; 10(24):eadk5108.

PMID: 38875334 PMC: 11177932. DOI: 10.1126/sciadv.adk5108.


Screening Strategies to Reduce COVID-19 Mortality in Nursing Homes.

Dong S, Jutkowitz E, Giardina J, Bilinski A JAMA Health Forum. 2024; 5(4):e240688.

PMID: 38669030 PMC: 11065177. DOI: 10.1001/jamahealthforum.2024.0688.


References
1.
Mercer T, Salit M . Testing at scale during the COVID-19 pandemic. Nat Rev Genet. 2021; 22(7):415-426. PMC: 8094986. DOI: 10.1038/s41576-021-00360-w. View

2.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View

3.
Kissler S, Fauver J, Mack C, Olesen S, Tai C, Shiue K . Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies. PLoS Biol. 2021; 19(7):e3001333. PMC: 8297933. DOI: 10.1371/journal.pbio.3001333. View

4.
Grassly N, Pons-Salort M, Parker E, White P, Ferguson N . Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study. Lancet Infect Dis. 2020; 20(12):1381-1389. PMC: 7434438. DOI: 10.1016/S1473-3099(20)30630-7. View

5.
Shah A, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R . Effect of Vaccination on Transmission of SARS-CoV-2. N Engl J Med. 2021; 385(18):1718-1720. PMC: 8451182. DOI: 10.1056/NEJMc2106757. View